Format

Send to:

Choose Destination
See comment in PubMed Commons below
Yale J Biol Med. 2011 Dec;84(4):361-9.

Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.

Author information

  • 1Department of Epidemiology of Microbial Diseases and Global Health, Yale School of Public Health, New Haven, Connecticut 06510, USA. jonathan.p.smith@yale.edu

Abstract

Drug-resistant tuberculosis is quickly emerging as one of the largest threats to the global health community. Current chemotherapy for tuberculosis dates back to the 1950s and is arduous, lengthy, and remains extremely difficult to complete in many of the highest burdened areas. This causes inadequate or incomplete treatment, resulting in genetic selection of drug-resistant strains. With a dearth of novel anti-TB drug candidates in the development pipeline, nanoparticle technology allows us to take current chemotherapies and deliver them more efficaciously, reducing the frequency and duration of treatment and increasing bioavailability. This approach can improve patient adherence, reduce pill burden, and shorten time to completion, all which are at the heart of drug resistance. This review examines the multiple advantages of nanoparticle drug delivery of tuberculosis chemotherapy and summarizes the challenges in implementation.

KEYWORDS:

ATDs; MDR-TB; chemotherapy; drug-resistant tuberculosis; nanoparticle; tuberculosis

PMID:
22180674
[PubMed - indexed for MEDLINE]
PMCID:
PMC3238330
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk